^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Kanjinti (trastuzumab-anns) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
05/16/2018
Excerpt:
Kanjinti in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
Secondary therapy:
capecitabine; cisplatin + 5-fluorouracil
Source:
Title:
Efficacy analyses of central laboratory pCR results from the LILAC study comparing the biosimilar ABP 980 and trastuzumab.
Published date:
05/16/2018
Excerpt:
The phase 3 LILAC Study compared ABP 980 with trastuzumab (TRAS) on pathologic complete response (pCR) in women with HER2+ early breast cancer....pCR was achieved in 48.0% for ABP 980 and 40.5% for TRAS, based on local review. RD of pCR was 7.3% (90% CI: 1.2%, 13.4%); RR was 1.19 (90% CI: 1.033, 1.366). The upper limit of the CIs slightly exceeded the equivalence margin. Based on central review, pCR was achieved in 47.8% for ABP 980 and 41.8% for TRAS
DOI:
10.1200/JCO.2018.36.15_suppl.583
Trial ID:
